Lj. Vleming et al., The DD genotype of the ACE gene polymorphism is associated with progression of diabetic nephropathy to end stage renal failure in IDDM, CLIN NEPHR, 51(3), 1999, pp. 133-140
Background: The insertion-deletion (I/D) polymorphism of the angiotensin co
nverting enzyme gene is a diallelic polymorphism that constitutes a genetic
influence on the progression of renal diseases such as IgA nephropathy. Pa
tients with the DD genotype have an accelerated progression towards end sta
ge renal failure in these diseases. The role of the I/D polymorphism in the
pathogenesis of diabetic nephropathy in IDDM is unresolved. Patients and m
ethods: We therefore set out to study the contribution of the I/D polymorph
ism in 79 patients (age 39.5 +/- 7.6 years (mean +/- SD) with end stage ren
al failure due to diabetic nephropathy, who were recipients of a combined k
idney-pancreas transplantation (n = 60), or who were on the waiting list fo
r such a procedure (n = 19). The control series consisted of 82 patients (a
ge 39.5 +/- 9.6 years) without microalbuminuria after fifteen years of IDDM
. Results: The ACE genotype distribution in patients was not in accordance
with the Hardy-Weinberg equilibrium due to a significant overrepresentation
of the DD genotype (X-2 = 8.9, p = 0.01). This resulted in a significant i
ncrease of the D-allele frequency in the cases compared to controls (X-2 =
4.9, p = 0.03). The presence of one D-allele did not increase the risk of e
nd stage renal failure (odds ratio ID/II = 1.0, 95% Cl 0.4 - 2.2). The pres
ence of the DD genotype increased the risk of end stage renal failure twofo
ld compared to the other genotypes (odds ratio 2.1, 95% Cl 1.1 - 4.0). The
risk estimate seemed slightly higher in patients with good metabolic contro
l (odds ratio 2.6, 95% Cl 1.0 - 7.1), than in patients with poor control (o
dds ratio 1.6, 95% Cl 0.59 - 4.3). Conclusion: It is concluded that the ris
k of end-stage renal failure in patients with IDDM is twofold increased in
patients with the DD genotype as compared to patients with other genotypes.